Who are Lactobacillus plantarum strain 299v's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lactobacillus casei variety rhamnosus granules, Lactobacillus Crispatus M247, INF108F probiotic, E. coli Nissle suspension, lactobacillus LB, Bacillus Licheniformis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lactobacillus-plantarum-strain-299v.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lactobacillus plantarum strain 299v — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lactobacillus plantarum strain 299v (Lactobacillus plantarum strain 299v) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live biotherapeutic product; probiotic. Area: Oncology; Immunology.

phase 3 Live biotherapeutic product; probiotic Oncology; Immunology Biologic Live · refreshed every 30 min

Target snapshot

Lactobacillus plantarum strain 299v (Lactobacillus plantarum strain 299v) — Children's Oncology Group. Lactobacillus plantarum strain 299v is a probiotic bacterium that modulates the gut microbiome and enhances intestinal barrier function and immune tolerance.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Lactobacillus plantarum strain 299v TARGET	Lactobacillus plantarum strain 299v	Children's Oncology Group	phase 3	Live biotherapeutic product; probiotic
Lactobacillus casei variety rhamnosus granules	Lactobacillus casei variety rhamnosus granules	Seoul National University Hospital	marketed	Probiotic / Live biotherapeutic product
Lactobacillus Crispatus M247	Lactobacillus Crispatus M247	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Live biotherapeutic product
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
E. coli Nissle suspension	E. coli Nissle suspension	University of Hohenheim	marketed	Live biotherapeutic product (probiotic)
lactobacillus LB	lactobacillus LB	Hospital General de Mexico	marketed	Live biotherapeutic product / Probiotic
Bacillus Licheniformis	Bacillus Licheniformis	Asan Medical Center	phase 3	Live biotherapeutic product (LBP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live biotherapeutic product; probiotic class)

Children's Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lactobacillus plantarum strain 299v — Competitive Intelligence Brief. https://druglandscape.com/ci/lactobacillus-plantarum-strain-299v. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab